223 related articles for article (PubMed ID: 25342378)
1. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
Atkinson BJ; Cauley DH; Ng C; Millikan RE; Xiao L; Corn P; Jonasch E; Tannir NM
BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
[TBL] [Abstract][Full Text] [Related]
3. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
4. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
5. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
6. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in renal cell carcinoma.
Wang Y
Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
[TBL] [Abstract][Full Text] [Related]
8. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
9. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
[TBL] [Abstract][Full Text] [Related]
11. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
Park K; Kim HJ; Lee JL; Lee KH; Jeong IG; Song C; Hong BS; Hong J; Kim CS; Ahn H
Anticancer Res; 2014 Oct; 34(10):5723-8. PubMed ID: 25275080
[TBL] [Abstract][Full Text] [Related]
12. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
[TBL] [Abstract][Full Text] [Related]
13. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
Nozawa M; Nonomura N; Ueda T; Nishimura K; Kanayama HO; Miki T; Nakatani T; Tomita Y; Azuma H; Yoshioka T; Tsujihata M; Uemura H
Jpn J Clin Oncol; 2013 Nov; 43(11):1132-8. PubMed ID: 23999768
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
Penttilä P; Donskov F; Rautiola J; Peltola K; Laukka M; Bono P
Eur J Cancer; 2017 Aug; 81():9-16. PubMed ID: 28586749
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
19. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
20. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
Miyake H; Fujisawa M
Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
